Promising early results for rare psoriasis drug

NCT ID NCT03619902

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was to see if the drug could safely control symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imsidolimab (a lab-made antibody that targets inflammation)
What this could lead to: If successful, this could point toward a new treatment option to control flare-ups in people with generalized pustular psoriasis.
What could go wrong: This is a very small early-phase trial with only 8 participants, so results may not apply to everyone. The drug may not work in larger studies or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED PUSTULAR PSORIASIS

Contacts and locations

Locations

Site 100

Ann Arbor, Michigan, 48109, United States
Site 101

Indianapolis, Indiana, 46250, United States
Site 102

Encino, California, 91436, United States
Site 104

Miami, Florida, 33316, United States
Site 105

Largo, Florida, 33771, United States
Site 201

London, United Kingdom
Site 202

Salford, United Kingdom
Site 203

Newcastle upon Tyne, United Kingdom
Site 301

Rzeszów, 35-055, Poland
Site 302

Lodz, Poland
Site 303

Lodz, 90-436, Poland
Site 304

Olsztyn, 10-229, Poland
Site 501

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.